Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › MCRB Leadership & Pay · Oct 26, 2026
Seres Therapeutics CFO Marella Thorell resigns effective November 15 MCRB Seres Therapeutics, Inc.
Marella Thorell resigned as Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc., effective November 15, 2026. Following her departure, she is expected to provide advisory services to support an orderly transition on terms to be agreed upon between Ms. Thorell and the Company. The filing does not disclose a successor or severance details.
More from Seres Therapeutics, Inc. Reports Q3 net loss of $16.3M, plans FDA submission for SER-155 irEC study in Q1 2027 Nov 4, 2026 Seres Therapeutics reported a net income of $4.6 million for Q2 2026, driven by a $25 million gain from the Nestlé… Aug 5, 2026 Seres Therapeutics entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus… Aug 4, 2026 At its reconvened 2026 Annual Meeting of Stockholders on July 8, 2026, Seres Therapeutics, Inc. stockholders approved… Jul 8, 2026 Seres Therapeutics, Inc. announced top-line results from an Investigator-Sponsored Trial (IST) evaluating SER-155 in… Jul 8, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
